Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Cumberland Pharmaceuticals (CPIX) EBIAT (2016 - 2025)

Cumberland Pharmaceuticals' EBIAT history spans 16 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, EBIAT rose 25.76% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$2.8 million, up 55.92%, while the annual FY2025 figure was -$1.4 million, 78.09% up from the prior year.
  • EBIAT for Q4 2025 was -$1.4 million at Cumberland Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • Across five years, EBIAT topped out at $1.3 million in Q1 2025 and bottomed at -$3.8 million in Q4 2021.
  • The 5-year median for EBIAT is -$1.1 million (2024), against an average of -$972153.8.
  • The largest annual shift saw EBIAT skyrocketed 233.79% in 2021 before it tumbled 1204.25% in 2024.
  • A 5-year view of EBIAT shows it stood at -$3.8 million in 2021, then soared by 34.49% to -$2.5 million in 2022, then surged by 57.82% to -$1.1 million in 2023, then tumbled by 78.86% to -$1.9 million in 2024, then increased by 25.76% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's EBIAT are -$1.4 million (Q4 2025), -$1.9 million (Q3 2025), and -$740740.0 (Q2 2025).